DNA X, Inc.
SONM Nasdaq· Telephone & Telegraph Apparatus
Last close · Oct 27, 2026
$2.96
KIRA · Stoqly’s AI analyst, in plain words
- DNA X, Inc. lost $20.7M in fiscal 2025.
- DNA X, Inc. owes $3.8M more than it holds in cash.
Market cap
$4.0M
P/E
—
Revenue
—
Net income
−$20.7M
Free cash flow
—
Operating margin
—
DNA X, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$20.7M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What DNA X, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Apr 15, 2026
- Legal name
- DNA X, Inc.
- CIK
- 0001178697
DNA X, Inc. · SONM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $54.6M | $69.8M | $93.6M | $58.3M | — |
| Revenue growth | −14.7% | 28.0% | 34.1% | −37.7% | — |
| Gross margin | 11.8% | 16.6% | 20.6% | 17.0% | — |
| Operating margin | −69.6% | −20.5% | 0.5% | −5.3% | — |
| Net income | −$38.6M | −$14.1M | −$0.1M | −$33.6M | −$20.7M |
| Net margin | −70.8% | −20.2% | −0.1% | −57.7% | — |
| Diluted EPS | −$4.08 | −$0.49 | −$0.02 | −$128.37 | −$28.58 |
| Cash | |||||
| Cash from operations | −$38.5M | −$12.4M | −$4.1M | −$8.5M | −$23.5M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.2M | — |
| Free cash flow | −$38.5M | −$12.4M | −$4.1M | −$8.7M | — |
| FCF margin | −70.6% | −17.7% | −4.4% | −14.9% | — |
| Share count change | 104.8% | 205.2% | −85.2% | −93.9% | 175.7% |
| Debt and strength | |||||
| Cash and short-term investments | $11.2M | $13.2M | $9.4M | $5.3M | $1.3M |
| Debt incl. finance leases | $0.2M | $0.1M | — | — | $5.1M |
| Shareholders' equity | $18.6M | $20.0M | $22.4M | −$5.7M | −$8.0M |
| Current ratio | 1.7x | 1.4x | 1.4x | 0.7x | 0.6x |
| Interest coverage | — | −147.3x | — | — | −5.7x |
| Returns and quality | |||||
| Return on capital | −394.4% | −161.8% | — | — | — |
| Return on equity | −164.2% | −72.8% | −0.4% | −403.7% | — |
| Return on tangible equity | −207.3% | −70.3% | −0.4% | — | — |
| Piotroski F-score | 3 | 4 | 5 | 2 | — |
| Altman Z'' | −21.6 | −14.9 | −12.4 | −25.8 | −26.8 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
DNA X, Inc. · SONM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.96 a share, the company is worth $4.0M.
Source: SEC EDGAR XBRL filings (CIK 0001178697). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.